STOCK TITAN

Chemomab Therapeutics Ltd - CMMB STOCK NEWS

Welcome to our dedicated news page for Chemomab Therapeutics (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Chemomab Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Chemomab Therapeutics's position in the market.

Rhea-AI Summary
Chemomab Therapeutics (Nasdaq: CMMB) receives a new patent from the European Patent Office for CM-101, a monoclonal antibody targeting CCL24 for treating liver diseases, including Primary Sclerosing Cholangitis. The patent extends protections in key European markets and complements existing patents in the U.S., Europe, Israel, and other regions. CM-101 is currently in Phase 2 SPRING trial for PSC, with promising results expected by mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
clinical trial
-
Rhea-AI Summary
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) announced accelerated Phase 2 CM-101 PSC trial timeline with topline data expected in mid-2024, extended cash runway, and achievements positioning the company for potential transformation in 2024. The company aims to advance CM-101 for fibro-inflammatory diseases and achieve clinical proof-of-concept.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.63%
Tags
earnings
-
Rhea-AI Summary
Chemomab Therapeutics Ltd. CEO, Dr. Adi Mor, will present at the Leerink Partners Global Biopharma Conference on March 12, 2024, in Miami. The presentation aims to showcase the company's innovative therapeutics for fibro-inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
Rhea-AI Summary
Chemomab Therapeutics Ltd. (CMMB) completes patient enrollment for CM-101 Phase 2 trial for treating Primary Sclerosing Cholangitis, with topline data expected in mid-2024. New patents granted in Brazil and Israel enhance protection for CM-101 in fibrotic liver diseases, including PSC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.35%
Tags
clinical trial
-
Rhea-AI Summary
Chemomab Therapeutics Ltd. (CMMB) will release its fourth quarter and full year 2023 financial results and provide a business update on March 7, 2024. The company focuses on developing therapeutics for fibro-inflammatory diseases with high unmet needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences earnings
-
Rhea-AI Summary
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced that CEO Dr. Adi Mor and other senior management will participate in two upcoming investor conferences. Dr. Mor will deliver a corporate presentation and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference and the Leerink Partners Global Biopharma Conference. The Oppenheimer Conference presentation will be webcast live and available on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.49%
Tags
conferences
Rhea-AI Summary
Chemomab Therapeutics Ltd. announced the publication of proteomic analyses that demonstrate the unique role of the soluble protein CCL24 in driving pathologies associated with the rare fibrotic liver disease primary sclerosing cholangitis (PSC). The company's first-in-class CCL24-neutralizing antibody CM-101 has the potential to interrupt these destructive processes. The Phase 2 PSC trial for CM-101 has completed patient enrollment, with topline data targeted for midyear 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
none
-
Rhea-AI Summary
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced the early completion of patient enrollment in its Phase 2 clinical trial assessing CM-101 as a treatment for primary sclerosing cholangitis (PSC). The company expects to report topline data from the PSC clinical trial by midyear 2024, rather than in the second half of 2024 as previously projected. CM-101 is a first-in-class monoclonal antibody with dual anti-inflammatory and anti-fibrotic activity, and it has Orphan Drug designation for PSC in the U.S. and the European Union (EU), as well as Fast Track designation by the U.S. Food & Drug Administration (FDA).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
clinical trial
-
Rhea-AI Summary
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) reports on its study analyzing serum samples and clinical data from systemic sclerosis (SSc) patients, revealing high serum CCL24 levels associated with severe manifestations of the disease, including pulmonary arterial hypertension (PAH). The company's first-in-class monoclonal antibody, CM-101, is designed to neutralize CCL24 and normalize CCL24-driven fibro-inflammatory disease processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.22%
Tags
none
Rhea-AI Summary
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) has been granted Fast Track designation by the FDA for CM-101, a first-in-class monoclonal antibody designed to treat primary sclerosing cholangitis (PSC), a fibrotic liver disease. The Phase 2 SPRING trial is advancing towards completion of enrollment with the top-line readout expected in 2H 2024. CM-101's unique dual anti-fibrotic and anti-inflammatory activity has demonstrated potential disease-modifying effects in preclinical and early clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.93%
Tags
clinical trial
Chemomab Therapeutics Ltd

Nasdaq:CMMB

CMMB Rankings

CMMB Stock Data

10.61M
190.59M
16.62%
24.99%
1.43%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
Tel Aviv

About CMMB

chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).